Following successful clinical trials for its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, Sirona Biochem (TSXV:SBM) is pursuing a path to commercialization for a final cosmetic product, according to the companyâs…
Canada’s biotech sector is home to companies pursuing cutting-edge therapies and medical technologies. Looking ahead into 2024, some market participants expect to see more investor interest in biotech as a…
Taking a position in a life science exchange-traded fund (ETF)provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a…
Sirona Biochem (TSXV:SBM) is looking forward to securing a licensing deal after a clinical trial for its novel anti-aging compound TFC-1326 showed exceptional results, according to Géraldine Deliencourt-Godefroy, the company’s…
Pull quotes were provided by Investing News Network clients Avricore Health and Sirona Biochem. This article is not paid-for content. Nearly every industry faced financial difficulties in 2022. Even biotech,…